BTIG Maintains Buy on Innoviva, Raises Price Target to $42

Benzinga Newsdesk www.benzinga.com Positive 81.9%

Neg 0% Neu 0% Pos 81.9%

BTIG analyst Julian Harrison maintains Innoviva (NASDAQ:INVA) with a Buy and raises the price target from $35 to $42.

Comments

No comments yet. Be the first!